Polycystic kidney disease (PKD) is genetic in nearly all cases. It is the most common life-threatening inherited kidney disorder, affecting up to 12 million people worldwide. The disease comes in two forms, each caused by mutations in specific genes and passed down through different inheritance patterns. Even in the roughly 10% of cases where there is no known family history, the cause is still genetic, typically a new (spontaneous) mutation that appeared for the first time in that person.
The Two Genetic Forms of PKD
PKD comes in two distinct types, and they differ in which genes are involved, how they’re inherited, and when symptoms appear.
Autosomal dominant PKD (ADPKD) is by far the more common form, with a prevalence of roughly 1 in 500 to 1,000 live births. It’s caused by a mutation in one of two genes: PKD1 or PKD2. Symptoms usually don’t appear until adulthood, though there is significant variability. Two people in the same family carrying the same mutation can have very different disease courses, because other genes, environmental factors, and even random biological events influence how the disease progresses.
Autosomal recessive PKD (ARPKD) is much rarer and far more severe. It’s caused by mutations in a gene called PKHD1 and almost always presents in childhood, often before birth. Roughly 30 to 50% of affected newborns die shortly after birth due to severely underdeveloped lungs. Those who survive infancy commonly develop enlarged kidneys, high blood pressure, liver scarring, and chronic kidney disease.
How Each Type Is Inherited
In autosomal dominant inheritance (ADPKD), only one copy of the mutated gene is needed to cause the disease. If one parent carries the mutation, each child has a 50% chance of inheriting it, and the disease has 100% penetrance. That means everyone who inherits the mutation will develop cysts, though the severity varies widely.
Autosomal recessive inheritance (ARPKD) requires two copies of the mutated gene, one from each parent. Both parents are typically carriers with no symptoms of their own. When two carriers have a child, there’s a 25% chance the child inherits both copies and develops the disease, a 50% chance the child becomes a carrier, and a 25% chance the child inherits no mutated copies at all.
PKD1 vs. PKD2: Why the Gene Matters
For ADPKD, which of the two genes is mutated makes a real difference in how the disease plays out. People with PKD1 mutations generally have a more aggressive course. Those with PKD2 mutations tend to develop symptoms 10 to 20 years later and are less likely to reach kidney failure. This distinction matters for long-term planning, because it can shape how doctors monitor kidney function over time and when dialysis or transplantation might become necessary. About 5 to 10% of adults who need dialysis or a kidney transplant have ADPKD.
What If No One in Your Family Has It?
About 10% of people diagnosed with ADPKD report no family history of the disease. This doesn’t mean the cause isn’t genetic. In some of these cases, a parent carried the mutation but was never diagnosed, perhaps because their disease was mild or they died of something else before kidney problems appeared. In other cases, the mutation is genuinely new. A study at the University of Colorado confirmed spontaneous mutations in 6 out of 24 patients who had no family history, after verifying biological parentage and ruling out other explanations. So even without a family connection, PKD remains a genetic disease.
How PKD Is Diagnosed
For people with a known family history, ultrasound is typically the first step. It detects kidney cysts with nearly 90% sensitivity, and in people over 30 with a PKD1 mutation, ultrasound-based criteria approach 100% accuracy. For younger individuals or those with PKD2 mutations, ultrasound is less reliable. In people under 30 with PKD2, sensitivity drops to around 67%.
Genetic testing is the most sensitive diagnostic method overall, capable of identifying the specific mutation involved. It’s less commonly used as a first-line tool because of cost and complexity, but it becomes valuable when the diagnosis is uncertain, when there’s no family history, or when someone needs a definitive answer for family planning purposes.
Options for Family Planning
If you know you carry a PKD mutation, there are options to reduce the chance of passing it to your children. Preimplantation genetic testing, done during in vitro fertilization, allows embryos to be screened for the specific mutation before implantation. Only embryos without the disease-causing variant are transferred. This option is becoming increasingly popular among people with ADPKD, particularly because the disease doesn’t manifest until later in life, giving families time to make informed reproductive choices.
Prenatal genetic testing during pregnancy is also available. For families weighing these decisions, identifying the exact mutation through genetic testing beforehand is an important first step, since the screening tools need to know precisely what to look for.
Gene Therapy on the Horizon
Researchers at Mayo Clinic have developed a gene-editing approach that directly corrects a single-letter DNA mutation in the PKD1 gene using a technique called base editing, a refined form of CRISPR. In preclinical studies, a single treatment slowed cyst growth, improved heart and liver health, and extended survival. The therapy was delivered using a viral vector and corrected the mutation in a significant proportion of kidney cells. Work is now focused on whether the approach can help after cysts have already formed and on developing alternative delivery methods, including nanoparticles. If it translates to humans, it could reduce or eliminate the need for lifelong medication and delay kidney failure.